Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension

International Heart Journal

Volumn 52, Issue 5, 2011, Pages 323-326

  Maki, Hisataka ^a   Yao, Atsushi ^a   Inaba, Toshiro ^a   Shiga, Taro ^a   Hatano, Masaru ^a   Kinugawa, Koichiro ^a   Yamashita, Takeshi ^b   Aizawa, Tadanori ^b   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b THE CARDIOVASCULAR INSTITUTE   (Japan)

Author keywords

Beraprost; Bosentan; Combination therapy; Pulmonary arterial hypertension; Tadalafl

Indexed keywords

BERAPROST; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; DILTIAZEM; DIURETIC AGENT; NITRIC OXIDE; OXYGEN; TADALAFIL;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOPULMONARY EXERCISE TEST; CASE REPORT; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE SEQUENCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; ECG ABNORMALITY; EXERCISE TOLERANCE; FEMALE; HEART INDEX; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMIC PARAMETERS; HOSPITAL ADMISSION; HUMAN; LEG EDEMA; NORMAL VALUE; OXYGEN THERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SYMPTOM; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; CARBOLINES; CARDIAC OUTPUT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EPOPROSTENOL; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; MIDDLE AGED; SULFONAMIDES; VASODILATOR AGENTS;

EID: 80054752045     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.52.323     Document Type: Article

References (10)

1. Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403. (Review)
2. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S78-S84. (Review)
3. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), Endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-537.
4. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-11.
5. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart. Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-619.
6. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermey-er J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26: 858-63.
7. Rich S, Pogoriler J, Husain AN, Toth PT, Gomberg-Maitland M, Archer SL. Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest 2010; 138: 1234-9.
8. Deb S, Yun J, Burton N, Omron E, Thurber J, Nathan SD. Reversal of idiopathic pulmonary arterial hypertension and allograft pneumonectomy after single lung transplantation. Chest 2006; 130: 214-7.
9. Levy NT, Liapis H, Eisenberg PR, Botney MD, Trulock EP. Path-ologic regression of primary pulmonary hypertension in left native lung following right single-lung transplantation. J Heart Lung Transplant 2001; 20: 381-4.
10. Rich S. The current treatment of pulmonary arterial hypertension: time to redefined success. Chest 2006; 130: 1198-202. (Review)